medigraphic.com
ISSN 0210-5187 (Electronic)

2015, Number 2

<< Back Next >>

Med Cutan Iber Lat Am 2015; 43 (2)

JAK inhibitors: a new therapeutic door in alopecia areata

Sevilla-González FK, Ferrando J

Language: Spanish
References: 16
Page: 90-92
PDF size: 218.56 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Petukhova L, Duvic M, Hordinsky M, Norris D, Prince V, Shimomura Y et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010; 466: 113-117.

  2. Xing L, Dai Z, Jabbari A, Cerise J, Higgins C, Gong W et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014; 20: 1043-1049.

  3. Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014; 134 (12): 2988-2990.

  4. Amos G, Amos E, Ralf P. Alopecia areata. N Eng J Med. 2012; 366: 1515-1525.

  5. Sundberg JP, Cordy WR, King LE Jr. Alopecia areata in aging C3H/HeJ mice. J Invest Dermatol. 1994; 102: 847-856.

  6. McElwee KJ, Boggess D, King LE Jr, Sundberg JP. Experimental induction of alopecia areata-like hair loss in C3H/HeJ mice using full-thickness skin grafts. J Invest Dermatol. 1998; 111: 797-803.

  7. Freyschmidt-Paul P, McElwee KJ, Hoffmann R, Sundberg JP, Vitacolonna M, Kissling S et al. Interferon-g-deficient mice are resistant to the development of alopecia areata. Br J Dermatol. 2006; 155: 515-521.

  8. Gilhar A, Kam Y, Assy B, Kalish RS. Alopecia areata induced in C3H/HeJ mice by interferon-γ: evidence for loss of immune privilege. J Invest Dermatol. 2005; 124: 288-289.

  9. Freyschmidt-Paul P, McElwee KJ, Hoffmann R, Sundberg JP, Kissling S, Hummel S et al. Reduced expression of interleukin-2 decreases the frequency of alopecia areata onset in C3H/HeJ mice. J Invest Dermatol. 2005; 125: 945-951.

  10. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010; 115: 3109-3117.

  11. O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013; 72: ii111-ii115.

  12. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011; 186: 4234-4243.

  13. Papp KA, Menter A, Strober B, Langley R, Buonanno M, Wolk R et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012; 167: 668-677.

  14. Mattei P, Corey K, Kimball Ab. Psoriasis area severity index (PASI) and the dermatology life quality index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014; 28: 333-337.

  15. Gershon E. In hairless man, arthritis drug spurs hair growth –lots of it. Yale News. 2014; 19.

  16. Hsu L, Armstrong AW. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. J Immunol Res. 2014; 2014: 283617.




2020     |     www.medigraphic.com